We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
- Authors
Montagut, C; Iglesias, M; Arumi, M; Bellosillo, B; Gallen, M; Martinez-Fernandez, A; Martinez-Aviles, L; Cañadas, I; Dalmases, A; Moragon, E; Lema, L; Serrano, S; Rovira, A; Rojo, F; Bellmunt, J; Albanell, J
- Abstract
The validation of KRAS mutations as a negative marker of response to anti-epidermal growth factor receptor (EGFR) antibodies has meant a seminal advance towards treatment individualisation of colorectal cancer (CRC) patients. However, as a KRAS wild-type status does not guarantee a response to anti-EGFR antibodies, a current challenge is the identification of other biomarkers of response. On the basis of pre-clinical evidence, we hypothesised that mitogen-activated protein kinase phosphatase-1 (MKP-1), a phosphatase that inactivates MAPKs, could be a mediator of resistance to anti-EGFR antibodies.
- Publication
British journal of cancer, 2010, Vol 102, Issue 7, p1137
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/sj.bjc.6605612